A survey of physician receptivity to molecular diagnostic testing and readiness to act on results for early-stage colon cancer patients.

ABSTRACT:

Background

We sought to assess physician interest in molecular prognosic testing for patients with early stage colon cancer, and identify factors associated with the likelihood of test adoption.

Methods

We identified physicians who care for patients with early-stage (pN0) colon cancer patients, mailed them a survey, and analyzed survey responses to assess clinician receptivity to the use of a new molecular test (GUCY2C) that identifies patients at risk for recurrence, and clinician readiness to act on abnormal test results.

Results

Of 104 eligible potential respondents, 41 completed and returned the survey. Among responding physicians, 56 % were receptive to using the new prognostic test. Multivariable analyses showed that physicians in academic medical centers were s

SUBMITTER: Myers RE 

PROVIDER: S-EPMC5048478 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature